OncoMatch/Clinical Trials/NCT07241767
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Is NCT07241767 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin and FH-006 ; SHR-1316 ; BP102 for lung cancer.
Treatment: FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin · FH-006 ; SHR-1316 ; BP102 — Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor treatment
Receive other anti-tumor treatments within 4 weeks before the first medication
Cannot have received: chest radiation therapy
Chest radiation therapy patients who received>30 Gy within 24 weeks prior to the first use of the investigational drug
Lab requirements
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify